Replies to post #160393 on Biotech Values

[mcbio]

DYAX

As they noted in cc, FDA no longer considers HAE as unmet medical need, thus need large controlled trial from now on.

I assume you are talking specifically about acute treatment. What about DYAX's DX-2930, which is a potential prophylactic drug for HAE.

[biomaven0]

>HAE

need large controlled trial from now on.

And that is mighty expensive because they will have to pay for the Cinryze.

Peter